- Conditions
- Healthy
- Interventions
- IPI-145 (duvelisib), IPI-145
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–42
of 42
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • Portland, Oregon
- Conditions
- Anaplastic Lymphoma Kinase, Anaplastic Large Cell Lymphoma
- Interventions
- Alectinib, Duvelisib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Duvelisib, Ofatumumab
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 37
- States / cities
- La Jolla, California • Denver, Colorado • Altamonte Springs, Florida + 32 more
- Conditions
- Lymphoma, Relapsed/Refractory T-cell Lymphomas
- Interventions
- Romidepsin, Bortezomib, duvelisib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 11
- States / cities
- Stanford, California • Boston, Massachusetts • St Louis, Missouri + 7 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Duvelisib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Healthy
- Interventions
- IPI-145, Midazolam
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Chronic Lymphocytic Leukemia, Richter Syndrome
- Interventions
- Duvelisib, Venetoclax
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 7
- States / cities
- Miami, Florida • Brewer, Maine • Boston, Massachusetts + 1 more
- Conditions
- Mycosis Fungoides, Cutaneous T-cell Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- IPI-145, Ofatumumab
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 14
- States / cities
- La Jolla, California • Denver, Colorado • Fort Myers, Florida + 9 more
- Conditions
- Unresectable Melanoma
- Interventions
- Nivolumab, Duvelisib
- Drug
- Lead sponsor
- John Kirkwood
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hematologic Malignancies
- Interventions
- IPI-145 (duvelisib)
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 4
- States / cities
- New York, New York • Columbus, Ohio • Nashville, Tennessee + 1 more
- Conditions
- Indolent Non-Hodgkin Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Whittier, California • Denver, Colorado + 20 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Duvelisib, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Chicago, Illinois • Harvey, Illinois + 7 more
- Conditions
- Hematologic Malignancy
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more
- Conditions
- Indolent Non-Hodgkin Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 6
- States / cities
- Fort Myers, Florida • Lecanto, Florida • Orange City, Florida + 3 more
- Conditions
- CD20+ Follicular Lymphoma
- Interventions
- Duvelisib, Rituximab, Obinutuzumab
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • Hackensack, New Jersey + 2 more
- Conditions
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more